A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628

NCT ID: NCT06840925

Last Updated: 2025-02-21

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-24
• Study Completion Date: 2025-06-30

Brief Summary

A phase I clinical trial to evaluate the relative bioavailability of PRAX-628 tablet formulation compared to capsule formulation

Detailed Description

This Phase 1, randomized, open-label, 2-way crossover clinical trial is designed to investigate the relative bioavailability, pharmacokinetics (PK), safety, and tolerability of PRAX628 tablet formulation and PRAX-628 capsule formulation in healthy male or female participants.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Oral Dose 40mg PRAX-628 tablet then 4x10mg PRAX-628 capsules

40 mg PRAX-628 tablet followed by 4×10 mg PRAX-628 capsules administered orally.

Group Type: EXPERIMENTAL

PRAX-628

Intervention Type: DRUG

Once daily oral

Single Oral Dose 4x10mg PRAX-628 capsules then 40mg PRAX-628 tablet

4×10 mg PRAX-628 capsules followed by 40 mg PRAX-628 tablet administered orally.

Group Type: EXPERIMENTAL

PRAX-628

Intervention Type: DRUG

Once daily oral

Interventions

PRAX-628

Once daily oral

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Weight of at least 50 kg with body mass index (BMI) between 18 and 32 kg/m2
• Is in good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations
• All females have a negative pregnancy test and are not planning to get pregnant for the duration of the trial
• Female of non-childbearing potential by reason of surgery or at least 1 year post menopause

Exclusion Criteria

• Any clinically significant abnormalities, medical, or psychiatric conditions identified by a detailed medical history, or physical examination
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs. Examples of such conditions include (but are not limited to):

1. History of inflammatory bowel syndrome, gastritis, gastrointestinal or rectal bleeding

2. History of major gastrointestinal tract surgery (ie, gastrectomy, bowel resection, cholecystectomy etc.)

3. History or evidence of pancreatic injury or pancreatitis

• History or presence of impaired renal function supported by estimated glomerular filtration rate [eGFR]<60 mL/min/1.73m2 or clinically significant abnormal urinary constituents (eg, protein)
• History of cancer except for nonmelanoma skin cancer resected >2 years ago and that has been definitively treated and considered cured.
• History of any lifetime suicide attempt or active suicidal ideation with intent as indicated by a "Yes" response to either Question 4 or 5 on the C-SSRS "Baseline/ Screening" version
• History of left bundle branch block, arrhythmias, Brugada syndrome, congenital heart disease, familial short QT syndrome, or family (first degree relative) history of sudden death, ventricular or clinically significant arrhythmias, including idiopathic ventricular fibrillation.
• Abnormal standard 12-lead ECG after at least 5 minutes resting in the supine position
• Abnormal vital signs after at least 5 minutes resting in the supine position:
• Has any of the following: a serum total bilirubin value >1.1× the upper limit of normal (ULN), a serum alanine aminotransferase (ALT) value >1.5×ULN, or aspartate aminotransferase (AST) value >1.5×ULN
• Serology test positive for human immunodeficiency virus (HIV), or hepatitis B or C
• Known allergy or hypersensitivity to any component of the formulation of PRAX 628 or history of severe allergy or anaphylaxis to a drug, food, or other exposure
• Use of any experimental or investigational drug or device within 30 days prior to the first dose of study drug or 5 times the terminal half-life of the drug, whichever is longer
• Use of systemic prescription medications; or over-the-counter medication, including multivitamins; and dietary and herbal supplements within 2 weeks or 5 times the terminal half-life of the medication prior to the first dose of study drug (whichever is longer) and for the duration of the trial
• Donation of blood within 1 month prior to Screening, plasma within 1 week prior to Screening, or platelets within 6 weeks prior to Screening
• Any vaccination within 28 days of the first dose of study drug

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Praxis Precision Medicines

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Director, Clinical Development

Role: STUDY_DIRECTOR

Praxis Precision Medicines

Locations

Nucleus Network Melbourne

Melbourne, Victoria, Australia

Countries

Australia

Central Contacts

Head of Pharmacovigilance

Role: CONTACT

clinicaltrials@praxismedicines.com

617-300-8460

Facility Contacts

Nucleus Network Melbourne

Role: primary

melbourne@nucleusnetwork.com

1800 243 733

Other Identifiers

PRAX-628-104

Identifier Type: -

Identifier Source: org_study_id